Print | Email Page

Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in China

December 2018

Jones Day represented Incyte Pharmaceuticals in its strategic collaboration and license agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment of hematological and oncological diseases. Innovent pays a $40 million upfront fee to Incyte, and Incyte is entitled to receive future development milestones totaling up to $129 million and commercialization milestones totaling up to $202.5 million plus tiered royalties. Incyte is entitled to co-promote each of the commercial products with Innovent.

For additional information about this matter, please contact: Thomas A. Briggs

Client(s): Incyte Corporation